Study effect of Baicalein encapsulated/loaded Chitosan-nanoparticle on allergic Asthma pathology in mouse model.
| Autor: | Wang D; Department of Internal Medicine of Traditional Chinese Medicine, People's Hospital of Yanting County, Sichuan 621600, China., Mehrabi Nasab E; Cardiologist, Department of Cardiology, School of Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran., Athari SS; Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Saudi journal of biological sciences [Saudi J Biol Sci] 2021 Aug; Vol. 28 (8), pp. 4311-4317. Date of Electronic Publication: 2021 Apr 20. |
| DOI: | 10.1016/j.sjbs.2021.04.009 |
| Abstrakt: | Asthma as chronic airway disease has high prevalence in children and imbalance of Th1/Th2 is a critical mechanism in pathogenesis of the asthma. Baicalein as a cell protective and anti-inflammatory flavonoid may have anti-asthma effect. Therefore, for better using lung, baicalein was used in chitosan-nanoparticle as anti-asthma treatment. Baicalein was loaded and encapsulated in chitosan nanoparticle. The morphology, physical characters (particle size, zeta potential and FT-IR) were analyzed. Drug encapsulation and loading capacity, accumulative release-time were studied. After asthma model producing, the mice were treated with L-B-NP and E-B-NP. At least, MCh challenge test, Cytokines measurement and Lung Histopathology were done. Nanoparticles had average size 285 ± 25 nm with negative charge -2.5 mV. The L-B-NP decreased penh value and E-B-NP decreased inflammation. Both nanoparticles increased IL-12 and decreased IL-5. Also, L-B-NP decreased mucus secretion in bronchi. L-B-NP and E-B-NP control immune-allergo-inflammatory response of asthma. L-B-NP controlled AHR and E-B-NP controlled inflammation that can be used as controlling anti-asthma drug. (© 2021 The Author(s).) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|